ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-OR035

Empagliflozin (EMPA) and Incidence of Rapid Decline in eGFR in Patients with Type 2 Diabetes (T2D) and Established Cardiovascular Disease (CVD): An Exploratory Analysis from the EMPA-REG OUTCOME Trial

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 305 CKD: Clinical Trials and Tubulointerstitial Disorders

Authors

  • Hadjadj, Samy, University Hospital Centre, Poitiers, France
  • Thomas, Merlin C, Monash University, Melbourne, Victoria, Australia
  • Cooper, Mark E., Monash University, Melbourne, Victoria, Australia
  • Koitka-Weber, Audrey, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
  • Hantel, Stefan, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
  • von Eynatten, Maximilian, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
  • Wanner, Christoph, Würzburg Univ Clinic, Würzburg, Germany
Background

The eGFR progressively declines in most patients with T2D. In some patients a more rapid decline in eGFR is observed, putting them at risk for the consequences of uremia and ultimately end-stage renal disease. In the EMPA-REG OUTCOME® trial, EMPA was associated with slower progression of kidney disease. In this post-hoc analysis, we evaluated the effect of EMPA on the incidence of patients experiencing a more rapid decline in eGFR.

Methods

7020 patients with T2D and established CVD were randomized (1:1:1) to EMPA 10 mg, 25 mg or placebo (PBO) in addition to standard of care. Change in eGFR decline over the study period (from baseline to follow-up) was calculated by utilizing linear regression models. A rapid decline in eGFR was defined by an annual decline in eGFR ≥5 ml/min/1.73m2. Logistic regression analysis was used to investigate differences between EMPA vs PBO groups.

Results

At baseline, mean (SD) eGFR was 74.0 (21.4) ml/min/1.73m2. Over the study period, 354 participants (5.1%) experienced a rapid decline in eGFR, including 8.9% in the PBO group and 3.2% in participants receiving EMPA. After adjusting for other risk factors, this equated to two-thirds reduction in risk (Figure, odds ratio 0.33 [95% CI 0.26, 0.41]; p<0.0001) among participants receiving EMPA. A similar reduction among EMPA-treated participants in the incidence of patients experiencing a rapid decline in eGFR was also observed using a lower threshold (Figure).

Conclusion

Patients treated with EMPA were significantly less likely to experience a rapid decline in eGFR over approximately 3 years of treatment. This finding suggests that EMPA may have the potential to reduce the incidence of chronic renal failure in T2D in the long term.

Funding

  • Commercial Support